Evidence map›Paper›PMID 41510137›Full record

ArticleACS omega2025

Quantification of Interactions between Small Molecules and RNA Probes Representative of Myotonic Dystrophy Type 1 Using Affinity Capillary Electrophoresis and UPLC-UV.

Mathieu Leveque, Mathilde Wells, Delphine Beukens, Victor Lefebvre, Stéphanie Hambye, Bertrand Blankert

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mathieu LevequeLaboratory of Pharmaceutical Analysis, Faculty of Medicine Pharmacy and Biomedical Sciences, Health Research Institute, University of Mons, Place du Parc 20, 7000 Mons, Belgium.
Mathilde WellsLaboratory of Pharmaceutical Analysis, Faculty of Medicine Pharmacy and Biomedical Sciences, Health Research Institute, University of Mons, Place du Parc 20, 7000 Mons, Belgium.
Delphine BeukensLaboratory of Pharmaceutical Analysis, Faculty of Medicine Pharmacy and Biomedical Sciences, Health Research Institute, University of Mons, Place du Parc 20, 7000 Mons, Belgium.
Victor LefebvreLaboratory of Pharmaceutical Analysis, Faculty of Medicine Pharmacy and Biomedical Sciences, Health Research Institute, University of Mons, Place du Parc 20, 7000 Mons, Belgium.
Stéphanie HambyeLaboratory of Pharmaceutical Analysis, Faculty of Medicine Pharmacy and Biomedical Sciences, Health Research Institute, University of Mons, Place du Parc 20, 7000 Mons, Belgium.
Bertrand BlankertLaboratory of Pharmaceutical Analysis, Faculty of Medicine Pharmacy and Biomedical Sciences, Health Research Institute, University of Mons, Place du Parc 20, 7000 Mons, Belgium.ORCID https://orcid.org/0000-0002-6667-7677

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myotonic dystrophy type 1 (OMIM #160900) is a multisystemic, autosomal, and dominantly inherited pathology. It is characterized by an expansion (>50) of trinucleotides [CTG]

Identifiers

PMID41510137
PMCPMC12777318

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.